CLOs on the Move

Merus

www.merus.nl

 
Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.merus.nl
  • 1 Broadway
    Cambridge, MA USA 02142
  • Phone: 781.760.0013

Executives

Name Title Contact Details
Peter Silverman
Executive Vice President and General Counsel Profile

Similar Companies

GreenwichBiosciences

Greenwich Biosciences is the leader in researching cannabinoid medicines for rare epilepsies like Dravet Syndrome, LGS, TSC, and others.

Vidantus Alliance

Vidantus Alliance is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abner Labs

Abner Innovation Laboratories Limited (“Abner Labs”) is a British Columbia, Canada, company formed to acquire Abner Technology Group Limited (“Abner Group”), owner of the ibetmobile sports viewing and betting technology platform. This proprietary, artificial intelligence (“AI”) driven smart technology makes watching and wagering on live sports on any online device as easy as playing video games.

Context Therapeutics

Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.